



TM

SYSTEMATIX INSTITUTIONAL EQUITIES

Systematix

Institutional Equities

16 October 2025

Nestlé India

Topline spurt excites; margins still subdued; valuation lofty

RESULT UPDATE

Sector: FMCG Rating: HOLD

CMP: Rs 1,280 Target Price: Rs 1,250

Stock Info

Sensex/Nifty	83,468/ 25,585
Bloomberg	NEST IN
Equity shares (mn)	1928.31
52-wk High/Low	Rs 1,286/1,058
Face value	Rs 1
M-Cap	Rs2,462bn/\$28.6bn
3-m Avg Turnover	US\$ 19.1mn


Financial Snapshot (Rs mn)

Y/E Mar	FY26E	FY27E	FY28E
Sales	219,714	242,191	265,243
PAT	30,302	34,923	39,165
EPS (Rs)	15.7	18.1	20.3
PE (x)	81.5	70.7	63.0
EV/EBITDA (x)	49.4	44.1	39.7
P/BV (x)	53.0	45.9	40.0
EV/Sales	11.2	10.1	9.2
RoE (%)	69.9	69.6	67.9
RoCE (%)	91.7	95.8	92.9
NWC (days)	7	7	7
Net gearing (x)	(0.2)	(0.3)	(0.4)

Shareholding Pattern (%)

	Aug 25	Jun 25	Mar 25
Promoter	62.8	62.8	62.8
-Pledged	-	-	-
FII	10.0	10.3	10.0
DII	11.4	11.2	11.3
Others	15.8	15.8	15.9

Stock Performance (1-year)



Abhishek Mathur

abhishekmathur@systematixgroup.in

+91 22 6704 8059

Rajat Parab

rajatparab@systematixgroup.in

+91 22 6704 8084

The good news – broad-based growth revival, though on a low base: Nestlé India (NEST) delivered 2QFY26 revenues and earnings ahead of our and consensus estimates. Nestle's revenue growth at 11% YoY – the highest in 9 quarters and the first instance of double-digit growth in more than two years – was powered by volume growth of c.7% YoY (our est.), albeit on a low base (volume decline of c.2% in 2QFY25). **More positively, we understand Nestle's channel management post the September GST cuts** was relatively better vs most other large listed peers – the company likely encountered only a few days of trade disruption/ destocking, with low/ minimal impact on growth and realizations.

Broad-based topline performance: Prepared Dishes & Cooking Aids (c.30% of sales) produced strong double-digit growth; **Maggi witnessed double-digit volume growth** with improving market share, backed by pricing interventions for *Noodles* in rural markets. **Confectionery and Beverages** (combined c.30% of sales) maintained their trajectory of strong double-digit growth; chocolates were supported by rural acceleration and premiumization (*KitKat* leading growth here); coffee was driven by consumer upgrades to premium offerings (*Gold*) and low-price packs to recruit new consumers. In **Milk Products & Nutrition** (c.40% of sales), **we view the commentary on strong performance in infant nutrition as a significant positive** (we est. mid-single digit YoY value growth here), coming on the back of a decline in FY25, with Nestle launching low/no-sugar variants of *Ceregrow*.

The wrinkle – subdued margins, and a mixed outlook on commodity costs: On the flipside, 2Q gross margin (GPM) declined 230bps YoY and another 90bps QoQ to 54.3% on elevated cost-inflation in milk, edible oils, coffee. Management issued what we view as a **cautious outlook on raw material costs** – softer milk prices, stable/ lower coffee costs but firm/ higher edible oil costs and balanced cocoa. While we expect sequential pickup in GPM in 2H26, we have lowered our estimates in view of the evolving input-cost situation (edible oils still elevated, coffee prices volatile) and cautious management commentary. Operating margin (OPM) declined 100bps YoY while recovering 30bps QoQ, leading to EBITDA/ PAT growth of 6%/ 4% YoY.

Views: We see significant positives emerging for Nestle, with (1) volume-led turnaround in the key *Maggi* portfolio, (2) sustained strong growth in beverages and confectionery, and (3) recovery in key categories of Milks & Nutrition. However, we remain watchful of (1) consistency in volume growth delivery, (2) volatile input-cost inflation and (3) lofty valuations (stock trading at P/E of 71x on FY27E EPS). Product innovations should continue to support growth, punctuated by launches in breakfast cereals (*Munch Choco Fills*), RTD coffee, *noodles (spicy range)*, millet-based foods (oats noodles), toddler foods, chocolates (*KitKat* variants) and pet foods. We remain positive on sequential GPM benefits from (1) high pricing power in key categories supported by leadership positions, (2) premiumization-led mix improvement (evident in confectionery, coffee) and (3) innovative product launches in new categories.

Valuation: We raise our FY26E-FY28E revenue estimates by 1% but lower PAT estimates by 6-7% to factor in a protracted period of subdued margins, and build FY25-FY28E revenue/ PAT CAGR of 10%/9%. We maintain HOLD rating on Nestle; We roll over valuation to September-2027E (from June-2027E) and value NEST at a P/E of 65x, in-line with its long-period average, for an unchanged TP of Rs 1,250.

Investors are advised to refer disclosures made at the end of the research report.

Category Performances

- **Continued robust performance in Powered and Liquid Beverages:** Category delivered another high double-digit growth driven by mix of affordable price point packs and premium offerings such as NESCAFÉ Gold and NESCAFÉ Roastery. NESCAFÉ RTD continued to demonstrate strong growth. In coffee, NESCAFÉ solidified its leadership by gaining additional market share and increasing household penetration.
- **Volume-led growth in Confectionery:** Confectionery delivered strong double-digit growth, driven by significant volume growth. Category witnessed rural acceleration, premiumization and increased in-home penetration driven by quick commerce. KITKAT was the major growth driver and continued its market share gains. MUNCH, MILKYBAR continued their double-digit growth run. New launches include Salted Caramel and Hazelnut variants in premium KITKAT Delights range and Polo Sharebag.
- **Growth sustains in Prepared Dishes and Cooking Aids:** Accelerated volume growth stimulated strong double-digit value growth. MAGGI noodles recorded double-digit volume growth. Targeted pricing strategies for Maggi Noodles portfolio increased market share in rural regions. Also increased media spends. Masala-Ae-Magic continued its strong run.
- **Milk Products and Nutrition:** Overall the category had mixed performance, with certain segments showing growth and muted performance by others. In domestic market MILKMAID delivered strong growth. Toddler milks products delivered strong performance, gaining market share.
- **Pet Care:** The Pet food business reported double-digit growth, achieving its highest turnover since its integration into the Nestlé India business. PURINA FRISKIES had two new variant launches Meaty Grills and Indoor Delights.

Channels

- **Strong growth in e-commerce:** E-Commerce continued its growth momentum, supported by festive, thematic, and new product launches such as the KITKAT Delights Range and MAGGI Double Masala. Quick commerce accelerated.
- **Out-of-Home (OOH):** The business displayed strong double-digit growth. KITKAT spread gained momentum among chefs and dessert chain operators.
- **Organized Trade:** Strong broad-based growth across categories mainly driven by festive activations and scale-up of new product launches.
- **Exports:** Strong demand across the product groups led exports to high double-digit growth. MAGGI Noodles and its variants continued to perform well. Nestle expanded the portfolio to new geographies like NESCAFÉ bulk into the Middle East, NESCAFÉ Sunrise in the UAE, Saudi Arabia, Singapore, New Zealand, the KITKAT range in Singapore, and MILKMAID Doypack in Sri Lanka.

Commodity prices

Coffee prices are expected to stabilize and could decline due to normal upcoming crops in Vietnam and India. Correction in cocoa demand over the past two years may cause balanced supply-demand globally. Edible oil prices are anticipated to remain firm and may rise further due to tight demand-supply globally. Milk prices to soften post-festive season, with onset of the flush season.

Exhibit 1: Quarterly performance snapshot (Consolidated)


YE March (Rs mn)	Q2FY26	Q2FY25	YoY (%)	Q1FY26	QoQ (%)
Net Revenues	56,436	51,040	10.6	50,962	10.7
Raw material cost	25,781	22,139	16.4	22,854	12.8
(% of sales)	45.7	43.4		44.8	
Gross profit	30,656	28,901	6.1	28,107	9.1
(% of sales)	54.3	56.6	-230 bps	55.2	-83 bps
Employee cost	5,367	5,017	7.0	5,157	4.1
(% of sales)	9.5	9.8	-32 bps	10.1	-61 bps
Others	12,922	12,207	5.9	11,948	8.2
(% of sales)	22.9	23.9	-102 bps	23.4	-55 bps
EBITDA	12,366	11,677	5.9	11,003	12.4
EBITDA margin (%)	21.9	22.9	-97 bps	21.6	32 bps
Other income	16	69	(76.1)	40	(59.4)
PBIDT	12,383	11,746	5.4	11,043	12.1
Depreciation	1,634	1,216	34.3	1,569	4.1
Interest	464	322	44.0	469	(1.0)
PBT	10,285	10,208	0.8	9,005	14.2
Tax	2,753	3,010	(8.5)	2,412	14.1
ETR (%)	26.8	29.5		26.8	
Share of P&L of JV/associates	-100	-37	(97.3)	-126	(20.6)
Minority interest	0	0		0	
Adjusted PAT	7,432	7,161	3.8	6,466	14.9
PATAMI margin	13.2	14.0	-86 bps	12.7	48 bps
Extraordinary income/(exp.)	0	(1,834)		0	
Reported PAT	7,432	8,995	(17.4)	6,466	14.9
No. of shares (mn)	1,928.3	1,928.3		1,928.3	
Adj EPS (Rs)	3.9	3.7	3.8	3.4	

Source: Company, Systematix Institutional Research


Exhibit 2: Change in estimates

	Revised estimates			Old estimates			Variation (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Net sales	219,714	242,191	265,243	217,365	239,566	262,351	1.1%	1.1%	1.1%
EBITDA	49,875	55,704	61,536	51,950	57,975	64,014	-4.0%	-3.9%	-3.9%
EBITDA margin	22.70%	23.00%	23.20%	23.90%	24.20%	24.40%			
Adj. PAT	30,302	34,923	39,165	32,488	37,099	41,570	-6.7%	-5.9%	-5.8%


Source: Company, Systematix Institutional Research

Exhibit 3: Revenue/Adj PAT (Consol.) gr. at 10.6%/ 3.8% YoY


Source: Company, Systematix Institutional Research

Exhibit 4: Volume growth at 6.5% (our est.)


Source: Company, Systematix Institutional Research

Exhibit 5: Gross margin dropped by 230bps YoY

Source: Company, Systematix Institutional Research

Exhibit 6: EBITDA margin down by 100bps YoY

Source: Company, Systematix Institutional Research

Exhibit 7: Cut in SGA exp (-102bps YoY) and Emp exp (-32 bps YoY)

Source: Company, Systematix Institutional Research

Exhibit 8: Currently trades at 75x one-year forward earnings

Source: Company, Systematix Institutional Research

FINANCIALS

Profit & Loss Statement (Standalone)

YE: Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	1,95,634	2,02,016	2,19,714	2,42,191	2,65,243
Gross profit	1,10,863	1,14,518	1,21,941	1,35,869	1,49,597
GP margin (%)	56.7%	56.7%	55.5%	56.1%	56.4%
Operating profit	47,256	47,737	49,875	55,704	61,536
OP margin (%)	24.2%	23.6%	22.7%	23.0%	23.2%
Depreciation	4,373	5,399	6,476	6,996	7,346
Interest expense	1,133	1,360	1,838	1,577	1,654
Other income	1,143	589	177	194	214
Profit before tax	42,892	41,567	41,737	47,324	52,749
Taxes	11,022	11,085	10,985	12,201	13,585
Tax rate (%)	25.7%	26.7%	26.3%	25.8%	25.8%
Adj. PAT	31,870	30,242	30,302	34,923	39,165
Exceptional loss	92	1,834	-	-	-
Net profit	31,962	32,076	30,302	34,923	39,165
EPS	16.5	15.7	15.7	18.1	20.3

Source: Company, Systematix Institutional Research; Note: *FY24 is of 15 months

Balance Sheet

YE: Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Equity capital	964	964	1,928	1,928	1,928
Reserves	32,445	39,138	44,684	51,869	59,702
Debt	311	7,533	833	833	833
Deferred tax liab (net)	-	300	300	300	300
Other non current liabil.	32,581	35,173	36,725	38,354	40,065
Total liabilities	66,301	83,108	84,470	93,285	1,02,828
Fixed Asset	47,974	60,982	62,506	65,509	63,163
Investments	4,639	5,750	5,750	5,750	5,750
Other Non-current Asse.	18,071	17,859	18,446	19,063	19,710
Inventories	20,894	28,501	25,282	27,869	30,521
Sundry debtors	3,005	3,632	3,612	3,981	4,360
Cash & equivalents	7,789	957	6,572	12,425	24,485
Loans and Advances	2,861	4,252	3,250	3,576	3,770
Sundry creditors	22,379	23,735	24,680	27,205	29,794
Other current liabilities	16,551	15,090	16,268	17,684	19,137
Total Assets	66,301	83,108	84,470	93,285	1,02,828

Source: Company, Systematix Institutional Research

Cash Flow

YE: Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBIT	54,300	42,927	43,575	48,902	54,404
Depreciation	5,678	5,399	6,476	6,996	7,346
Tax paid	(12,988)	(10,244)	(10,985)	(12,201)	(13,585)
Working capital Δ	(2,489)	(7,112)	6,364	660	817
Other operating items	(1,342)	(1,841)	1,838	1,577	1,654
Operating cashflow	41,748	29,364	45,431	44,357	48,982
Capital expenditure	(18,827)	(20,086)	(8,000)	(10,000)	(5,000)
Free cash flow	22,921	9,277	37,431	34,357	43,982
Equity raised	-	-	964	-	-
Investments	2,838	(152)	-	-	-
Debt financing/disposal	-	7,257	(6,700)	-	-
Interest Paid	(260)	(337)	(1,838)	(1,577)	(1,654)
Dividends paid	(30,082)	(24,586)	(24,242)	(27,939)	(31,332)
Other items	(1,007)	(815)	588	1,629	1,711
Net Δ in cash	(1,976)	(7,227)	5,615	5,854	12,060

Source: Company, Systematix Institutional Research

Ratios

YE: Mar	FY24	FY25	FY26E	FY27E	FY28E
Revenue growth (%)	15.8	3.3	8.8	10.2	9.5
Op profit growth (%)	27.3	1.0	4.5	11.7	10.5
Net profit growth (%)	33.3	-5.1	0.2	15.3	12.1
OPM (%)	24.2	23.6	22.7	23.0	23.2
Net profit margin (%)	16.3	15.0	13.8	14.4	14.8
RoCE (%)	130.6	105.5	91.7	95.8	92.9
RoNW (%)	99.1	82.3	69.9	69.6	67.9
EPS (Rs)	16.5	15.7	15.7	18.1	20.3
DPS (Rs)	39.7	17.0	12.6	14.5	16.2
BVPS (Rs)	17.3	20.8	24.2	27.9	32.0
Debtor days	4	7	6	6	6
Inventory days	38	51	42	42	42
Creditor days	44	43	41	41	41
P/E (x)	77.4	81.6	81.5	70.7	63.0
P/B (x)	73.9	61.5	53.0	45.9	40.0
EV/EBITDA (x)	52.1	51.8	49.4	44.1	39.7

Source: Company, Systematix Institutional Research

DISCLOSURES/APPENDIX

I. ANALYST CERTIFICATION

I, **Abhishek Mathur, Rajat Parab**; hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by **Systematix Shares and Stocks (India) Limited (SSSIL)** or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

I. **ISSUER SPECIFIC REGULATORY DISCLOSURES**, unless specifically mentioned in point no. 9 below:

- The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
- The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
- The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
- The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
- The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
- SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
- The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
- The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
- Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

- There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

HOLD (H): The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

NOT RATED (NR): The analyst has no recommendation on the stock under review.

INDUSTRY VIEWS

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

II. **DISCLAIMER**

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSIL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSIL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSIL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSIL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSIL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSIL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSIL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSIL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSIL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSIL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSIL through this presentation.

SSSIL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.

Registration granted by SEBI to SSSIL and certification from NISM to the analyst in no way guarantee performance of SSSIL or to provide any assurance of returns to investors.



Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Tel no. 022-66198000/40358000 Fax no. 022-66198029/40358029 Email id contactus@systematixgroup.in. Visit us at: www.systematixgroup.in

Details of Compliance officer: Ms Nipa Savla, Compliance officer Tel no. 022-66198092/4035808092 Email id compliance@systematixgroup.in

Details of Email id grievance redressal cell : grievance@systematixgroup.in

Details of Registration : CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 12034600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | AMFI : ARN - 64917